Yamasa Of Japan In Deal With Merck To Develop New Type Of HIV Drug
This article was originally published in PharmAsia News
Japan's Yamasa has signed an agreement with Merck to develop an HIV/AIDS drug that laboratory studies suggested would be effective against highly resistant HIV strains.
You may also be interested in...
Merck & Co.'s vericiguat, an sGC stimulator, was approved for heart failure but it enters a competitive space with a narrow indication.
A top executive at the Swedish company spoke with Medtech Insight about how the mobility and data reliability of 5G cellular technology will change how medtech manufacturers design their products.
Roche's Actemra is a major player in this space, but Humanigen is looking to take it on directly.